Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

Wegovy Cuts Heart Attack, Stroke Risk 20% in Five-Year Trial

  • Post author:PacConAdmin
  • Post published:August 8, 2023
  • Post category:Uncategorized
  • Post comments:0 Comments

Enrolling 17,604 overweight adults aged 45 and over with established cardiovascular disease, Novo Nordisk’s five-year trial of Wegovy (semaglutide) for weight loss showed a 20 percent reduction in major adverse…

Continue ReadingWegovy Cuts Heart Attack, Stroke Risk 20% in Five-Year Trial

Quick Notes on Aug. 7, 2023

  • Post author:PacConAdmin
  • Post published:August 7, 2023
  • Post category:Uncategorized
  • Post comments:0 Comments

Source: Drug Industry Daily

Continue ReadingQuick Notes on Aug. 7, 2023

Stryker Launches Ad Campaign for Robotic-Assist Knee and Hip Replacements

  • Post author:PacConAdmin
  • Post published:August 7, 2023
  • Post category:Uncategorized
  • Post comments:0 Comments

Stryker has launched a national direct-to-consumer marketing campaign for its Mako SmartRobotics system for knee and hip replacement. Source: Drug Industry Daily

Continue ReadingStryker Launches Ad Campaign for Robotic-Assist Knee and Hip Replacements

Chamber, PhRMA Supreme Court Brief Supports Manufacturers in Anti-Terrorism Case

  • Post author:PacConAdmin
  • Post published:August 7, 2023
  • Post category:Uncategorized
  • Post comments:0 Comments

Pharmaceutical and medical device companies should not be held liable for terrorist actions after providing medical products to the Iraqi government, says an amicus brief from the U.S. Chamber of…

Continue ReadingChamber, PhRMA Supreme Court Brief Supports Manufacturers in Anti-Terrorism Case

Oncologist Group Blames Rebates and Discounts for Cancer Drug Shortages

  • Post author:PacConAdmin
  • Post published:August 7, 2023
  • Post category:Uncategorized
  • Post comments:0 Comments

The growing burden of rebates and discounts has left drugmakers “underwater” on manufacturing inexpensive, generic cancer drugs, and has significantly harmed the supply chain for these treatments, the Community Oncology…

Continue ReadingOncologist Group Blames Rebates and Discounts for Cancer Drug Shortages

Legislative Update — Week of Aug. 7, 2023

  • Post author:PacConAdmin
  • Post published:August 7, 2023
  • Post category:Uncategorized
  • Post comments:0 Comments

As the 118th Congress continues, FDAnews will track important pending legislation to keep you updated on laws and regulations that could impact your business. Source: Drug Industry Daily

Continue ReadingLegislative Update — Week of Aug. 7, 2023

Medicare Coverage for Novel Technologies Slow and Lacking, Say Stanford Researchers

  • Post author:PacConAdmin
  • Post published:August 4, 2023
  • Post category:Uncategorized
  • Post comments:0 Comments

Only 28 out of 64 medical device and diagnostic technologies, or 44 percent, requiring new Medicare coverage received reimbursement from 2016 to 2019, with the median time to at least…

Continue ReadingMedicare Coverage for Novel Technologies Slow and Lacking, Say Stanford Researchers

Regulatory Update — Week of Aug. 7, 2023

  • Post author:PacConAdmin
  • Post published:August 4, 2023
  • Post category:Uncategorized
  • Post comments:0 Comments

Over the past week, the FDA issued final guidance for waivers, exceptions, and exemptions from Section 582 of the FD&C Act, draft guidance for previously approved antiretrovirals for treatment of…

Continue ReadingRegulatory Update — Week of Aug. 7, 2023

Regulatory Update — Week of July 31, 2023

  • Post author:PacConAdmin
  • Post published:August 4, 2023
  • Post category:Uncategorized
  • Post comments:0 Comments

Over the past week, the FDA issued final guidance for waivers, exceptions, and exemptions from Section 582 of the FD&C Act, draft guidance for previously approved antiretrovirals for treatment of…

Continue ReadingRegulatory Update — Week of July 31, 2023

Nitrosamines Guidances Published by the FDA and EMA

  • Post author:PacConAdmin
  • Post published:August 4, 2023
  • Post category:Uncategorized
  • Post comments:0 Comments

The FDA and the European Medicines Agency (EMA) have both issued guidances on various aspects of detecting, measuring, limiting and avoiding the presence of nitrosamine impurities in pharmaceuticals. Source: Drug…

Continue ReadingNitrosamines Guidances Published by the FDA and EMA
  • Go to the previous page
  • 1
  • …
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.